SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the FDA accepting its supplemental BLA for the label expansion of Anktiva, setting a PDUFA date for early January 2027. Community discussion is heavily focused on the stock's significant short interest and the potential for a squeeze, with many longs pointing to the recent NCCN guideline updates and comparative clinical data as drivers for long-term growth despite near-term volatility.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock has hit a bottom, with many pointing to recent insider buying and high-profile endorsements as potential catalysts for a turnaround. However, community sentiment remains deeply divided, as traders express significant frustration over persistent price weakness and the stock's failure to maintain momentum.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the focal point of the market as investors anxiously await earnings results that many view as a critical bellwether for the entire AI infrastructure sector. The community is heavily divided, with intense debate over whether the stock will repeat its historical pattern of post-earnings selling or if it will catalyze a significant, sustained rally that boosts broader tech valuations.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing significant volatility and a sharp pullback as traders react to a broader market sell-off, surging bond yields, and persistent uncertainty surrounding global energy prices. While some community members are treating the drop as a long-term accumulation opportunity, many others are actively debating whether this signals a major trend reversal or if price manipulation is being used to clear out retail call positions.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate the final REGAL trial unblinding, with bullish sentiment fueled by management's recent commentary regarding extended GPS survival outcomes and its potential to outcompete existing maintenance therapies. The community is actively discussing an imminent short squeeze driven by heavy short interest and institutional accumulation, while emphasizing the importance of holding shares and avoiding stop-loss orders in anticipation of a transformative data readout.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending due to a recently announced $4.2 billion acquisition by Hapag-Lloyd at $35 per share, sparking intense community debate over the deal's viability, the potential for a bidding war, and the impact of the Israeli government's 'golden share' on final approval. Investors are actively discussing the arbitrage opportunity presented by the price gap between the current market value and the buyout offer, while weighing risks related to ongoing labor strikes and geopolitical tensions in the Middle East.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as investors react to a significant earnings beat and an optimistic full-year outlook, fueling debate over the company's turnaround progress under its new leadership. The community is actively discussing the stock's recent price recovery, comparing it to rival Walmart, and debating whether the rebound is a sustainable shift or a potential overextension.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending sharply higher after reporting strong quarterly earnings and raising its full-year guidance, which has fueled intense community discussion regarding its rapid expansion and market share growth. While bulls are highlighting the restaurant chain's robust same-store sales and healthy balance sheet as indicators for long-term potential, skeptics are actively debating whether the stock's premium valuation is sustainable in the current macro environment.

Analog Devices, Inc. is a semiconductor company, which engages in the combination of analog, digital, and software technologies into engineering solutions. Its products include analog and mixed signals, power management and reference, amplifiers radio frequency, and reference, sensors and actuators, and digital signal processing and system. The company was founded by Raymond P. Stata and Matthew Lorber in 1965 and is headquartered in Wilmington, MA.

Analog Devices Inc.

Analog Devices is trending following a strong quarterly performance where the company delivered a double beat on earnings and revenue, signaling a robust recovery in the analog semiconductor sector. Investors are particularly focused on the company's strategic acquisition of Empower Semiconductor to bolster its AI power delivery capabilities and its positive growth outlook across industrial and communications markets.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is trending following a double-beat earnings report and a raised full-year guidance that signal sustained demand momentum in AI infrastructure and testing. Investors and community members are actively debating the sustainability of this growth cycle, with many analyzing the company's role as a key supplier within the SpaceX supply chain and broader AI ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardio Diagnostics Holdings (NASDAQ: CDIO) Focused on Vision for Personalized Heart Care

Heart disease remains the leading cause of death worldwide, yet much of modern healthcare still focuses on reacting to cardiovascular events after they occur rather than identifying risk earlier and preventing disease progression.&#160;Cardio Diagnostics Holdings (NASDAQ: CDIO)&#160;is working to help reshape that paradigm through a vision centered on personalized, data-driven cardiovascular care powered by artificial [&#8230;]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource demands.&#160;Cardio Diagnostics Holdings (NASDAQ: CDIO)&#160;is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized [&#8230;]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management

Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies.&#160;Cardio Diagnostics Holdings (NASDAQ: CDIO)&#160;is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple blood [&#8230;]

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (Cardio Diagnostics or the Company), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the...

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD Test in India

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in...

Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced a new partnership with the Southdale YMCA to bring expanded heart health...

Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHDs Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart...

Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Company is partnering with YMCA of East Tennessee to launch a...

Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the...

Biotech stocks, particularly in the small- and mid-cap space, were hot topics among retail investors in 2024, often spurred by major announcements or clinical developments.&nbsp;Collectively, these stocks attracted significant chatter on Stocktwits.&nbsp;Here are the top five biotech stocks with the highest message volume growth this year:Tonix Pharmaceuticals Holding Corp. (TNXP): +47,066% Message VolumeTonix focuses on developing therapies to treat and prevent diseases. Its TNX-102 SL, a non-opioid analgesic for fibromyalgia, gained attention when the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">accepted</a> its New Drug Application in December. Earlier in the year, the company also reiterated its&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">commitment</a> to developing an mpox vaccine. Despite these milestones, TNXP shares are down over 97% this year.Candel Therapeutics Inc. (CADL): +16,000% Message VolumeCandel develops viral immunotherapies targeting cancer. Its lead product, CAN-2409, is under trial for various cancers, including prostate and non-small cell lung cancer. Positive late-stage&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">results</a> released this month for CAN-2409 in prostate cancer drove retail interest. Shares of CADL are up over 500% this year.Cardio Diagnostics Holdings Inc. (CDIO): +11,650% Message VolumeCardio Diagnostics gained traction with its AI-powered PrecisionCHD test for coronary heart disease. The test demonstrated significant cost-saving potential in healthcare, according to the company. Cardio also received final pricing determinations from the Centers for Medicare &amp; Medicaid Services for its products. Its stock has fallen nearly 63% year-to-date.Recursion Pharmaceuticals Inc. (RXRX): +9,600% Message VolumeRecursion uses AI and automation to discover medicines. A $50 million investment from Nvidia to support AI-driven drug discovery efforts primarily sparked significant retail interest this year, although RXRX shares have declined 22% so far in 2024.Galectin Therapeutics Inc. (GALT): +5,800% Message VolumeGalectin’s focus on fibrotic and inflammatory diseases, led by its drug belapectin, caught investors’ attention despite mixed trial results. While the drug didn’t meet statistical significance for a key endpoint in an early liver disease trial, further data analysis is expected in early 2025. GALT shares are down over 48% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

Equity

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercializes a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company was founded in 2007, and is headquartered in Chicago, IL.

CDIO
Cardio Diagnostics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDIO News

CDIOCardio Diagnostics Holdings Inc